175 Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest (2004) 113(9):1296-306. doi: 10.1172/JCI20295. Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature (2019) 569(7758):655-662. doi: 10.1038/s41586-019-1237-9. Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology (2005) 128(7):2020-8. doi: 10.1053/j.gastro.2005.03.046. Papadakis KA, Yang H, Ippoliti A, Mei L, Elson CO, Hershberg RM, et al. Anti-flagellin (CBir1) phenotypic and genetic Crohn’s disease associations. Inflamm Bowel Dis (2007) 13(5):524-30. doi: 10.1002/ibd.20106. Duck LW, Walter MR, Novak J, Kelly D, Tomasi M, Cong Y, et al. Isolation of flagellated bacteria implicated in Crohn’s disease. Inflamm Bowel Dis (2007) 13(10):1191-201. doi: 10.1002/ibd.20237. Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith Bk, Targan SR, et al. Sero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/ CARD15 genotype. Am J Gastroenterol (2004) 99(12):2376-84. doi: 10.1111/j.1572-0241.2004.40417.x. Choung RS, Princen F, Stockfisch TP, Torres J, Maue AC, Porter CK, et al. Serologic microbial associated markers can predict Crohn’s disease behaviour years before disease diagnosis. Aliment Pharmacol Ther (2016) 43(12) :1300-10. doi: 10.1111/apt.13641. van Schaik FD, Oldenburg B, Hart AR, Siersema PD, Lindgren S, Grip O, et al. Serological markers predict inflammatory bowel disease years before the diagnosis. Gut (2013) 62(5):683-8. doi: 10.1136/ gutjnl-2012-302717. Torres J, Petralia F, Sato T, Wang P, Telesco SE, Choung RS, et al. Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis. Gastroenterology (2020) 159(1):96-104. doi: 10.1053/j.gastro.2020.03.007. Lee SH, TurpinW, Espin-Garcia O, Raygoza Garay JA, Smith MI, Leibovitzh H, et al. Anti-Microbial Antibody Response is Associated With Future Onset of Crohn’s Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk. Gastroenterology (2021) S00165085(21)03243-1. doi: 10.1053/j.gastro.2021.07.009. Gacesa R, Kurilshikov A, Vich Vila A, Sinha T, Klaassen MAY, Bolte LA, et al. Environmental factors shaping the gut microbiome in a Dutch population. Nature (2022) 604:732-739 doi: 10.1038/s41586-022-04567-7. Bourgonje AR, Andreu-Sánchez S, Vogl T, Hu S, Vich Vila A, Gacesa R, et al. In-depth characterization of the serum antibody epitope repertoire in inflammatory bowel disease using phage-displayed immunoprecipitation sequencing. bioRxiv (2021) doi: 10.1101/2021.12.07.471581. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A (2008)105(43):16731-6. doi: 10.1073/pnas.0804812105. Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology (2010) 139(6):1844-1854.e1. doi: 10.1053/j.gastro.2010.08.049. Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, et al. Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon. Gut (2003) 52(2):237-42. doi: 10.1136/gut.52.2.237. Miltenyi S, Müller W, Weichel W, Radbruch A. High gradient magnetic cell separation with MACS. Cytometry (1990) 11(2):231-8. doi: 10.1002/cyto.990110203. Antimicrobial IgG immune responses in IBD 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51
RkJQdWJsaXNoZXIy MjY0ODMw